Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.
New York, New York--(Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...
We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...
Novo Nordisk’s annual results are out and they show the Danish pharmaceutical juggernaut earnt 290.4 billion Danish kroner last year (A$64 billion) — up 25%. Novo Nordisk boasts 45 million ...
It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results